Top

Published in:

Open Access 01-12-2017 | Research article

Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study

Authors: Tsuzumi Konishi, Satoshi Washino, Yuhki Nakamura, Masashi Ohshima, Kimitoshi Saito, Yoshiaki Arai, Tomoaki Miyagawa

Published in: BMC Urology | Issue 1/2017

Abstract

Background

Information on the safety of transurethral resection of bladder tumors (TURBT) in patients receiving anti-thromboembolic drugs is currently lacking. This study aimed to evaluate the clinical safety of TURBT in patients receiving anti-thromboembolic agents compared with patients not taking these agents and patients who interrupted their use perioperatively.

Methods

We retrospectively analyzed data for patients who underwent TURBT at Jichi Medical University Saitama Medical Center from September 2013 to August 2016.Patients who underwent surgery while receiving antiplatelet and/or anticoagulant drugs were allocated to the continuation group, those who interrupted these drugs comprised the interruption group, and those who did not use these agents were designated as the control group. We compared the patient characteristics, hemoglobin levels, and complications among the three groups.

Results

A total of 174 patients were analyzed including 19, 18, and 137 in the continuation, interruption, and control groups, respectively. There were no significant differences in patient and tumor characteristics, apart from age, among the three groups. Decreases in hemoglobin levels were similar in the continuation, interruption, and control groups (−0.50 g/dl, −0.40 g/dl, and −0.50 g/dl, respectively).Significantly more patients in the continuation group experienced clot retention compared with the control group (21% vs 5%, p = 0.03). Large tumor size tended to be a risk factor for clot retention in the continuation group (p = 0.07). No patient in the continuation or interruption group required blood transfusion, compared with two patients (1%) in the control group. No patients in any of the groups experienced cardiovascular events during their hospital stay or required rehospitalization for hematuria after discharge.

Conclusions

TURBT can be performed safely in patients who continue to take antiplatelet and/or anticoagulant agents, without increasing the risks of severe hemorrhage and blood transfusion. However, the risk of postoperative clot retention may be increased in these patients.

Culkin D, Exaire E, Green D, Soloway M, Gross A, Desai M, White J, Lightner D. Anticoagulation and Antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol. 2014;192(4):1026–34.CrossRefPubMed

Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli M, Pirlet C, Pomar J, Reifart N, Ribichini F, Schalij M, Sergeant P, Serruys P, Silber S, Uva M, Taggart D, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517–92.CrossRefPubMed

Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667–74.CrossRefPubMed

Wahl M. Dental surgery in anticoagulated patients. Arch of Intern Med. 1998;158(15):1610–6.CrossRef

Picozzi S, Marenghi C, Ricci C, Bozzini G, Casellato S, Carmignani L. Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease. Surg Endosc. 2014;28(1):116–21.CrossRefPubMed

Eberli D, Chassot P, Sulser T, Samama C, Mantz J, Delabays A, Spahn D. Urological surgery and Antiplatelet drugs after cardiac and Cerebrovascular accidents. J Urol. 2010;183(6):2128–36.CrossRefPubMed

Carmignani L, Picozzi S, Stubinski R, Casellato S, Bozzini G, Lunelli L, Arena D. Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. Surg Endosc. 2011;25(7):2281–7.CrossRefPubMed

Naspro R, Rossini R, Musumeci G, Gadda F, Da Pozzo L. Antiplatelet therapy in patients with coronary stent undergoing urologic surgery: is it still no Man's land? Eur Urol. 2013;64(1):101–5.CrossRefPubMed

Samama C, Bastien O, Forestier F, Denninger M, Isetta C, Juliard J, Lasne D, Leys D, Mismetti P, Grp E. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 - summary statement. Can J Anaesth. 2002;49(6):S26–35.PubMed

10.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi G, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126–30.CrossRefPubMed

11.

Straus S, Majumdar S, McAlister F. New evidence for stroke prevention - scientific review. JAMA. 2002;288(11):1388–95.CrossRefPubMed

12.

Llinas R. Could discontinuation of aspirin therapy be a trigger for stroke? Nat Clin Pract Neurol. 2006;2(6):300–1.CrossRefPubMed

13.

Bouillon K, Bertrand M, Boudali L, Ducimetiere P, Dray-Spira R, Zureik M. Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients with Nonvalvular Atrial Fibrillation Managed in Outpatient Care. J Am Heart Assoc. 2016;5(11).

14.

Latona J, Rahman A. Management of oral anticoagulation in the surgical patient. ANZ J Surg. 2015;85(9):620–5.CrossRefPubMed

Title: Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study
Authors: Tsuzumi Konishi
Satoshi Washino
Yuhki Nakamura
Masashi Ohshima
Kimitoshi Saito
Yoshiaki Arai
Tomoaki Miyagawa
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Urology / Issue 1/2017
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-017-0309-0

ACC 2024 Congress

Springer Medicine

Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer

Extranodal nasal-type natural killer/T-cell lymphoma with penile involvement: a case report and review of the literature

Canadian Men’s perspectives about active surveillance in prostate cancer: need for guidance and resources

The prostate cancer detection rates of CEUS-targeted versus MRI-targeted versus systematic TRUS-guided biopsies in biopsy-naïve men: a prospective, comparative clinical trial using the same patients

Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia